Positive. Strong growth in Biosimilars with improved margins over Generics.
• Net sales $5.232m +4% CC for H1
• Accelerated growth in Q2 at 5% CC; 8% reported.
• Biosimilars grew 11% to $1,496m.
• Core EBITDA $1,046m +20% organic; +18% reported.
• Margin upticked to 20% from 17.5%.
• Full-year 2025 guidance confirmed: mid-single-digit net-sales growth at CC and a core EBITDA margin of around 21%
• More biosimilar launches to come in H2. Core EBITDA margin to grow, reflecting mix of sales.
• Issued €500m 10yr in March and CHF400m. Next maturity Nov ’26.
Find more articles and bullets on these widgets:
| 3.25% Jan-44 Green DSL | Previous | |
| ISIN | NL0015001RG8 | |
| Amount | E2.055bln | E1.825bln |
| Avg yield | 3.176% | 2.976% |
| Avg Price | 101.01 | 104.00 |
| Pre-auction mid | 100.924 | 103.894 |
| Previous date | 09-Jul-24 |
New 7-year Dec-32 EU-bond
3.75% Oct-45 EU-bond tap:
For both:
From market source